Clinical Trial Update: First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study of EOS100850 (Inupadenant) in adults with solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• EOS100850 (Inupadenant) (Inupadenant)

Snippet

Sponsor: iTeos Therapeutics | Conditions: Solid Tumor, Adult | Phase 1 | Status: COMPLETED